Skip to main content
. 2020 Aug 5;20:578. doi: 10.1186/s12879-020-05305-y

Table 2.

Clinical characteristics of P. micra in case series, and in the literature cases

Characteristic Patients [no. (%) or as indicated] with:
Our case series (25) Literature cases (27)
Age yr: median (range) 83.0 (58–92) 59.0 (23–94)
Gender No.male/no.famale (ratio) 14/11 (1.3) 15/12 (1.3)
Community onset/nosocomial 23/2 26/1
Method of pathogen detection MALDI-TOF MS 23 6
16S rRNA sequencing 0 3
Biochemical test 2 4
Gas chromatography 0 6
Symptom Fever, no. (%) 23 (92.0) 12 (44.4)
Headache, no. (%) 0 2 (7.4)
Pharyngeal symptoms, no. (%) 1 (4.0) 0
Shortness of breath, no. (%) 0 2 (7.4)
Abdominal symptoms, no. (%) 1 (4.0) 3 (11.1)
Vomiting, no. (%) 1 (4.0) 1 (3.7)
Diarrhea, no. (%) 1 (4.0) 0
Myalgia, no. (%) 0 4 (14.8)
Shaking and/or chill, no. (%) 9 (36.0) 4 (14.8)
Low back pain, no. (%) 0 6 (22.2)
Underlying health status Steroid usage, no. (%) 1 (4.0) 0
Diabetes, no. (%) 6 (24.0) 3 (11.1)
Heart valve replacement, no. (%) 0 2 (7.4)
Malignancies, no. (%) 9 (36.0) 3 (11.1)
Diverticular disease, no. (%) 1 (4.0) 1 (3.7)
Abdominal operation within 4 weeks, no. (%) 1 (4.0) 0
Gastrointestinal perforation, no. (%) 1 (4.0) 0
Gynecologic disease, no. (%) 0 3 (11.1)
Charlson comorbidity score, median (range) 5 (0–7) N/Ra
Focus or likely source of infection Meningitis, no. (%) 0 1 (3.7)
Oropharyngeal, no. (%) 7 (28.0) 7 (25.9)
Endocarditis, no. (%) 0 3 (11.1)
Lung, no. (%) 1 (4.0) 0
Septic pulmonary emboli, no. (%) 1 (4.0) 3 (11.1)
Hepatobiliary (liver, pancreas, gallbladder, biliary), no. (%) 1 (4.0) 1 (3.7)
Gastrointestinal tract, no. (%) 6 (24.0) 3 (11.1)
Intraabdominal abscess, no. (%) 0 4 (14.8)
Pylephlebitis, no. (%) 0 2 (7.4)
Spondylodiscitis, no. (%) 1 (4.0) 8 (29.6)
Bacteremia with unknown source, no. (%) 9 (36.0) 4 (14.8)
Polymicrobial bacteremia no. (%) 12/25 (48) 5/27 (18.5)
Pitt bacteremia score median (range) 1 (0–13) N/R
Antibiotic sensitivity testing b Penicillin, no. (%) 22/22 (100) b 10/10 (100)
Ampicillin-sulbactam, no. (%) 12/12 (100) b 4/4 (100)
Piperacillin-tazobactam, no. (%) 12/12 (100) b 5/5 (100)
Meropenem, no. (%) 19/19 (100) b 5/5 (100)
Clindamycin, no. (%) 13/15 (86.7) b 9/9 (100)
All-cause mortality at: 30 days, no. (%) 1/25 (4.0) 1/27 (3.7)

aN/R not reported

bPercentage of susceptible isolates based on CLSI M100 S28 (2018) in our case series, presented as number of isolates with susceptibility/ number of isolates measured (susceptibility rate %)